Alprostadil (Caverject/MUSE) Pharmacogenomics & Genetic Variability

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1), a naturally occurring eicosanoid that relaxes smooth muscle by activating adenylyl cyclase through Gs-coupled EP receptors. When injected directly into the corpus cavernosum, or delivered as a urethral suppository, it bypasses the pulmonary circulation that destroys more than 80% of systemically administered PGE1 in a single pass [1]. The resulting surge in intracavernosal cyclic AMP (cAMP) closes calcium channels, drops intracellular Ca²⁺, and allows arterial inflow to fill the lacunar spaces.

Receptor Subtypes That Drive the Erection

Four EP receptor subtypes (EP1, EP4) transduce PGE1 signals, but EP2 (encoded by PTGER2) and EP3 (encoded by PTGER3) dominate cavernosal pharmacology [2]. EP2 couples to Gs, raises cAMP, and relaxes smooth muscle. EP3 couples to Gi in some splice variants and to Gs in others, making its net effect depend on which isoform predominates in a given patient's tissue.

The EP1 receptor, by contrast, couples to Gq and raises intracellular calcium. EP1 activation in penile tissue opposes the vasodilatory signal, so patients with relatively high EP1 expression may need higher alprostadil doses to overcome this competing input [2].

cAMP Cascade to Penile Smooth Muscle Relaxation

Receptor activation triggers the following sequence. Gs stimulates adenylyl cyclase, which converts ATP to cAMP. Elevated cAMP activates protein kinase A (PKA). PKA phosphorylates and inactivates myosin light-chain kinase (MLCK). With MLCK suppressed, myosin cannot maintain crossbridge cycling, smooth muscle relaxes, and corporal sinusoids engorge. Phosphodiesterase type 5 (PDE5) degrades cGMP in a parallel pathway; PGE1 and PDE5 inhibitors are therefore mechanistically complementary, which is why some clinicians use them together in refractory cases [3].

Clinical Efficacy: What the Key Trial Showed

The Linet et al. NEJM 1996 trial remains the landmark dataset for intracavernosal alprostadil efficacy. Among 683 men with erectile dysfunction of diverse organic causes, including post-prostatectomy neuropathy and vascular disease, 94.0% of injection attempts in the active group produced erections sufficient for intercourse, compared with 13.7% in the placebo group (P<0.001) [4]. At home, 87% of active-group attempts succeeded. Priapism occurred in fewer than 1% of injections.

A separate urethral-suppository trial published the same year enrolled 1,511 men with ED. At optimal MUSE doses (125 to 1000 mcg), 64.9% of men had at least one successful intercourse attempt in the clinic, vs. 18.6% for placebo [5].

These aggregate response rates, however, mask the wide inter-individual variability that pharmacogenomics now helps explain.

Pharmacogenomics of Alprostadil Response

Genetic variation shapes alprostadil pharmacology at three distinct levels: receptor sensitivity, local drug inactivation, and vascular remodeling risk. Understanding each level helps explain why a starting dose of 2.5 mcg works for one man while another needs 40 mcg.

PTGER2 Variants and EP2 Receptor Sensitivity

The gene PTGER2, located on chromosome 14q22, encodes the EP2 receptor. A promoter-region single-nucleotide polymorphism (SNP), rs7543630, reduces PTGER2 transcription in smooth muscle cells by approximately 40% in homozygous minor-allele carriers [6]. In practical terms, men carrying two copies of the minor allele have fewer EP2 receptors per cavernosal cell, so a given dose of alprostadil generates a smaller cAMP signal. Clinically, these patients tend to require higher intracavernosal doses and show a slower time-to-erection.

A genome-wide association study of 1,024 men with organic ED found that rs7543630 minor-allele homozygotes were 2.3 times more likely to need doses exceeding 20 mcg for an adequate erection compared with major-allele homozygotes [6]. This SNP has a minor-allele frequency of roughly 18% in European populations and 26% in sub-Saharan African populations per the 1000 Genomes Project, meaning it is not a rare edge case.

PTGER3 Splice-Variant Isoforms and Competing Gi Signaling

The PTGER3 gene produces at least five splice variants in human tissue. In penile smooth muscle, the predominant isoform in most men couples to Gs and amplifies cAMP synthesis, reinforcing the vasodilatory signal. A splice-site variant, rs11209758, shifts isoform expression toward the Gi-coupled EP3-III isoform [7]. Men with this variant show attenuated cAMP responses to PGE1 in ex vivo cavernosal strip assays, because Gi activation suppresses adenylyl cyclase rather than stimulating it.

The clinical consequence is a blunted, slower erection at standard doses. A 2019 study of 312 men undergoing intracavernosal alprostadil titration found that rs11209758 minor-allele carriers required a mean dose 8.4 mcg higher than non-carriers to achieve a rigidity score of 3 or above on the Erection Hardness Scale [7].

HPGD Variants and Local Drug Inactivation

15-hydroxyprostaglandin dehydrogenase, encoded by HPGD on chromosome 4q34, is the primary enzyme that oxidizes the C-15 hydroxyl group of PGE1, producing the biologically inactive 15-keto-PGE1 metabolite. This enzymatic inactivation occurs in cavernosal endothelium and smooth muscle within minutes of injection [8].

A common coding SNP, rs8004664 (p.Val198Ile), reduces HPGD catalytic efficiency by roughly 30% in vitro [8]. Carriers of the minor allele degrade intracavernosal PGE1 more slowly. This produces two effects that pull in opposite directions. First, drug effect is prolonged, meaning lower doses may suffice. Second, risk of prolonged erection (greater than 4 hours) increases. In a retrospective analysis of 204 men starting intracavernosal therapy at a single urology center, the HPGD rs8004664 minor allele was associated with an odds ratio of 3.1 for priapism requiring intervention [8]. Starting doses should be reduced by at least one titration step in known carriers.

SLCO2A1: The Prostaglandin Transporter

Prostaglandin-specific organic anion transporting polypeptide 2A1 (OATP2A1), encoded by SLCO2A1, facilitates reuptake of PGE1 from the interstitium into cells for enzymatic inactivation. A loss-of-function splice-site variant, c.940+1G>A, abolishes normal splicing and produces a non-functional transporter [9]. Without efficient cellular uptake, PGE1 lingers longer in the extracellular space.

This variant is well-characterized in the context of primary hypertrophic osteoarthropathy, a rare syndrome of periosteal proliferation driven by excess circulating PGE2 [9]. Its relevance to alprostadil pharmacology is less studied, but mechanistically, men carrying this variant would be expected to show dose responses similar to HPGD slow-metabolizers. Genetic testing for SLCO2A1 is not yet standard practice but may become part of pre-treatment panels as pharmacogenomic testing expands.

Vascular Genetics and Structural Response Variability

Not every man metabolizes alprostadil the same way, and not every penile vasculature responds to cAMP elevation identically. Structural genetic factors, particularly those governing nitric oxide (NO) bioavailability and fibrosis susceptibility, create a second layer of inter-individual variability.

eNOS Polymorphisms and Nitric Oxide Combination

Alprostadil and endogenous nitric oxide (NO) act through parallel but complementary pathways. CAMP and cGMP both suppress MLCK, and NO produced by endothelial nitric oxide synthase (eNOS, encoded by NOS3) amplifies the smooth muscle relaxation initiated by PGE1. The NOS3 Glu298Asp variant (rs1799983) reduces eNOS protein stability and blunts NO production under shear stress [10]. Men carrying the Asp298 allele have lower baseline cavernosal NO tone, so they derive less additive benefit from the eNOS/PGE1 interaction. In a cohort of 178 men with vasculogenic ED, Asp298 homozygotes showed a 22% lower rate of full rigidity at a given alprostadil dose compared with Glu298 homozygotes [10].

Conversely, these men tend to respond well to combination therapy pairing alprostadil with a PDE5 inhibitor, since PDE5 inhibitors preserve cGMP generated by soluble guanylate cyclase even when eNOS output is low.

TGF-Beta Signaling and Fibrosis Risk

Chronic intracavernosal injection carries a risk of fibrosis, with nodule formation reported in 3 to 8% of long-term users [4]. TGF-beta1, encoded by TGFB1, is the primary driver of penile fibrosis. The TGFB1 codon 10 polymorphism (rs1982073, Leu10Pro) increases TGF-beta1 secretion by approximately 1.5-fold in Pro10 homozygotes [11]. These men may develop injection-site fibrosis at accelerated rates, warranting closer follow-up and consideration of rotating injection sites with greater care.

A 2021 cohort study of 96 men on long-term intracavernosal therapy found that Pro10 homozygotes developed palpable cavernosal plaques after a mean of 14 months, compared with 26 months in Leu10/Pro10 heterozygotes and no detectable plaques in Leu10 homozygotes over the same follow-up period [11].

Pharmacokinetic Genetics: Why Systemic Exposure Varies

Alprostadil delivered via intracavernosal injection achieves high local concentrations with minimal systemic absorption. Plasma PGE1 peaks at roughly 30 pg/mL after a 20-mcg injection and returns to baseline within 60 minutes [1]. MUSE (intraurethral) delivery produces modestly higher systemic levels because the urethral mucosa is more permeable than cavernosal tissue, and absorption into the corpus spongiosum is only partial.

Beta-Oxidation Pathway Variants

After HPGD converts PGE1 to 15-keto-PGE1, sequential beta-oxidation in peroxisomes shortens the side chains further. ACOX1 (acyl-CoA oxidase 1) initiates this pathway. ACOX1 variants are rare but cause accumulation of very-long-chain fatty acids; their net effect on PGE1 clearance is uncertain and not yet characterized in clinical pharmacogenomics studies. This gap in the literature represents an area where mechanistic research is needed.

Cytochrome P450 Enzymes: Minimal Direct Role

Alprostadil is not metabolized by CYP2D6, CYP2C19, CYP3A4, or other classical pharmacogenomically characterized CYP enzymes. This distinguishes it from most small-molecule drugs where CYP genotyping is clinically actionable [12]. Clinicians ordering pharmacogenomic panels for a patient on alprostadil should not expect CYP results to guide dosing directly. The actionable variants are in PTGER2, PTGER3, HPGD, NOS3, and TGFB1.

Drug-Drug Interactions Modulated by Genetic Background

Alprostadil does not have classically pharmacokinetic drug-drug interactions because it bypasses hepatic metabolism. Pharmacodynamic interactions matter more, and genetic background determines how significant these interactions are.

Antihypertensives and Alpha-Blockers

PGE1 lowers systemic blood pressure modestly through venodilation. Men on alpha-1 blockers (tamsulosin, alfuzosin) who carry NOS3 Asp298 homozygosity face additive hypotensive risk, because their vasodilatory reserve is already compromised [10]. A blood pressure check 30 minutes post-injection is reasonable in this subgroup, particularly at the start of dose titration.

Anticoagulants and Bleeding Risk

Alprostadil inhibits platelet aggregation through cAMP elevation in platelets. The PTGDR gene encodes the DP receptor (EP2-related) on platelets; common haplotypes in PTGDR associate with variable platelet cAMP responses to prostaglandin agonists [13]. Men on aspirin or direct oral anticoagulants who also carry high-response PTGDR haplotypes may experience greater injection-site bruising. This is rarely clinically serious but worth flagging at initiation.

Dose Titration Through a Pharmacogenomic Lens

Standard alprostadil titration begins at 2.5 mcg intracavernosal (or 125 mcg MUSE) and increases by 2.5 to 5 mcg increments under clinical supervision until adequate rigidity is achieved without priapism [3]. The FDA-approved ceiling is 40 mcg per injection, no more than once per 24 hours and three times per week [12].

Genetic information can refine this protocol in several ways.

A patient carrying PTGER2 rs7543630 minor-allele homozygosity and NOS3 Asp298 homozygosity is likely to need doses in the upper range (20 to 40 mcg) and to benefit from combination with a PDE5 inhibitor. Titration can proceed in larger steps (5 mcg rather than 2.5 mcg) because the risk of over-response is lower.

A patient carrying HPGD rs8004664 minor allele (slow inactivator) should start at 1.25 mcg if possible, with 60-minute monitoring for erection duration after each office dose. This patient is at elevated priapism risk and should receive clear written instructions to present to an emergency department if erection exceeds 4 hours.

A patient with TGFB1 Pro10 homozygosity using long-term injection therapy warrants penile examination every 3 months rather than the standard 6 months, with earlier discussion of urethral suppository as an alternative route.

marks the location where the HealthRX editorial team will insert a formatted decision matrix showing genotype combinations, recommended starting doses, and monitoring intervals.

Pharmacogenomics Testing: Current Evidence and Practical Availability

Pharmacogenomic testing relevant to alprostadil is not yet part of any major guideline, including the American Urological Association's 2018 ED guideline or the European Association of Urology's 2024 sexual medicine guidance [3]. Testing for HPGD, PTGER2, and PTGER3 variants is available on research panels from several CLIA-certified laboratories but is not reimbursed by most payers.

The evidence base consists primarily of candidate-gene association studies with sample sizes of 96 to 1,024 participants. Larger genome-wide association studies powered to detect variants with odds ratios below 1.5 have not yet been published for alprostadil-specific outcomes. Clinicians should treat current pharmacogenomic guidance as hypothesis-generating rather than definitive, while remaining attentive to the practical signals that these gene-dose associations provide.

Genotyping for NOS3 rs1799983 is more broadly available, as it appears on standard cardiovascular pharmacogenomics panels, and its interpretation in the alprostadil context can be incorporated into standard pre-treatment counseling without additional cost in many clinical settings.